Barren Wuffet schreef op 12 oktober 2021 18:47:
[...]
Ik wel.
Heb je ook een ander voorbeeld?
COI Summary
The following list is a reflection of what has been reported to the IDSA.
To provide thorough transparency, the IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic.
Evaluation of such relationships as potential conflicts of interest is determined by a review process which includes assessment by the Board of Directors liaison to the Standards and Practice Guideline Committee and, if necessary, the Conflicts of Interest (COI) and Ethics Committee.
The assessment of disclosed relationships for possible COI is based on the relative weight of the financial relationship (i.e., monetary amount) and the relevance of the relationship (i.e., the degree to which an association might
reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration).
The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. L.B.
receives research funding from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, and Wellcome Trust,
and serves as chair of the Antimicrobial Drug Advisory Committee of the Food and Drug Administration.
V.C.
receives research funding from the Health and Medical Research Fund.
K. E. serves as a scientific advisor for
Merck, Bionet, IBM, Sanofi, X4 Pharmaceuticals, Inc., Seqirus, Inc.,
Moderna, Inc. and Pfizer, and
receives research funding from the Centers for Disease Control and Prevention and the National Institutes of Health.
R. G. has served on a scientific advisory board for Gilead Sciences, Inc., serves on a scientific advisory board for
Merck,
and receives research funding from the NIH.
J.G. serves in an advisory role for Qpex and Shionogi;
receives research funding from
Merk; previously served in an advisory role for Acceletrate, Achaogen, Astellas, Melinta, Nabriva, Paratek, scPharmaceutic, Spero and Tetraphase; and previously served on the speakers bureau for Astellas, Melinta,
Merck and Shiongi.
M.H.M
receives research funding from the Agency for Healthcare Research and Quality, the Endocrine Society, the Society for Vascular Surgery and The American Society of Hematology and is a Board member for the Evidence Foundation.
W.J.M. serves in an advisory role for Seqirus, Inc. and
receives research funding from Ansun Biopharma, Astellas Pharma,
AstraZeneca, Abbott Laboratories, Enanta Pharmaceuticals, Gilead Sciences, J
anssen Pharmaceuticals, Karius,
Merck, Melinta Therapeutics, Nabriva Therapeutics, Roche and Tetraphase Pharmaceuticals.
S.S. serves as an advisory board member for Amplyx Pharmaceuticals, Inc.; as an advisor/consultant to ReViral Ltd.; receives research funding from Ansun BioPharma, F2G, Shire (now Takeda), University of Nebraska, Cidara Therapeutics; and has served as an advisor for
Janssen Pharmaceutica and Acidophil.
A.H.S. receives research funding from the U.S. Department of Veterans Affairs.
Y.F.Y. receives honoraria for evidence reviews and teaching from the Evidence Foundation, honoraria for evidence reviews for the American Gastroenterological Association, and serves as a Director for the Evidence Foundation and for the U.S. GRADE Network.
All other authors: no disclosures reported.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
All other authors: no disclosures reported.